Panitumumab clinical trials
Also written ABX-EGF.
How each study uses Panitumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Panitumumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 27 Sept 2006 · VECTIBIX · BLA 125147 (FDA, Drugs@FDA)
- European Union
- 3 Dec 2007 · Vectibix · EMEA/H/C/000741 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
193 studies that test it; most in 2010 (33)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 5 |
| 2003 | 3 |
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 8 |
| 2007 | 10 |
| 2008 | 12 |
| 2009 | 18 |
| 2010 | 33 |
| 2011 | 18 |
| 2012 | 6 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 7 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 43 · Other 153
Amgen (34) · M.D. Anderson Cancer Center (6) · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) (6) · Vejle Hospital (6) · UNICANCER (5) · Vanderbilt-Ingram Cancer Center (5) · AIO-Studien-gGmbH (5) · Grupo Espanol Multidisciplinario del Cancer Digestivo (5)
Often tested with
Tested in the same studies.
Irinotecan (18) · Oxaliplatin (16) · Fluorouracil (13) · IRDye800 (13) · Bevacizumab (12) · Capecitabine (11) · FOLFIRI Regimen (8) · Carboplatin (8)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test Panitumumab.
- Nov 2026Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing SurgeryPhase 1/2 · Stanford University
- Jan 2027Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal CancerPhase 2 · M.D. Anderson Cancer Center
- Mar 2027Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing SurgeryPhase 1/2 · George Poultsides
- Apr 2027Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During SurgeryPhase 1/2 · Stanford University
- May 2027Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)Phase 2 · Gruppo Oncologico del Nord-Ovest
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
- Nov 2027A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical ProceduresPhase 1 · University of Alabama at Birmingham
- Nov 2027ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerEarly Phase 1 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses Panitumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 196
- Evaluating 111In Panitumumab for Nodal Staging in Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT05901545Written as Panitumumab
- Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT07741643Written as Panitumumab-IRDye800
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Panitumumab
- A Project Assessing the Safety and Feasibility of Using Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Ovarian Cancer During Surgical ProceduresNot yet recruitingPhase 1University of Alabama at BirminghamNCT07919509Written as Panitumumab-IRDye800
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 2AbbVieNCT06820463Written as Panitumumab
- Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical ProceduresRecruitingEarly Phase 1Eben RosenthalNCT07493447Written as Panitumumab-IRDye800
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Panitumumab
- Dynamic Changes in Circulating Tumour Cells Protein ExpressionRecruitingPhase 2Matteo's FriendsNCT06314997Written as panitumumab (EGFR inhibitors)
- Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During SurgeryRecruitingPhase 1/2Stanford UniversityNCT03582124Written as Panitumumab-IRDye800
- Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical ProceduresRecruitingPhase 1/2Stanford UniversityNCT04085887Written as Panitumumab-IRDye800
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingPhase 2Gruppo Oncologico del Nord-OvestNCT05845450Written as Panitumumab
- Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingPhase 3AmgenNCT06252649Written as Panitumumab
- Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT06819228Written as Panitumumab IRDye 800
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing SurgeryRecruitingPhase 1/2Stanford UniversityNCT03510208Written as Panitumumab
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingPhase 3SWOG Cancer Research NetworkNCT06998940Written as Panitumumab
- A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRIRecruitingPhase 1R-PharmNCT07543744Written as RPH-030
- Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing SurgeryRecruitingPhase 1/2George PoultsidesNCT03384238Written as Panitumumab
- Phase II Panitumumab-IRDye800 in Head & Neck CancerRecruitingPhase 2University of Alabama at BirminghamNCT04511078Written as Panitumumab-IRDye800
- Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal CancerRecruitingPhase 2UNICANCERNCT06245356Written as Panitumumab
- Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck CancerRecruitingPhase 1Vanderbilt-Ingram Cancer CenterNCT05945875Written as Panitumumab-IRDye800
See all 196 studies that test Panitumumab →
Given beside what is tested · 32 — Panitumumab is usual care or a partner of the new treatment
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP TrialRecruitingPhase 3ECOG-ACRIN Cancer Research GroupNCT05863195Written as Panitumumab
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal CancerRecruitingPhase 2Verastem, Inc.NCT07659795Written as panitumumab
- A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 1Genentech, Inc.NCT07859085Written as Panitumumab
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT07094204Written as panitumumab
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingPhase 1/2Institut de Recherches Internationales ServierNCT05786924Written as Panitumumab
- AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingPhase 1AmgenNCT07094113Written as Panitumumab
- A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C MutationRecruitingPhase 2AmgenNCT07172919Written as Panitumumab
- (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell CarcinomaRecruitingPhase 1Eben RosenthalNCT05747625Written as Panitumumab
- ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal CancerRecruitingPhase 2National Cancer Institute, NaplesNCT06714357Written as panitumumab
- Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the LiverRecruitingPhase 3Federation Francophone de Cancerologie DigestiveNCT02885753Written as Panitumumab
- Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02876107Written as Panitumumab
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the LiverCompletedPhase 2National Cancer Institute (NCI)NCT03366155Written as Panitumumab
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal CancerActive, not recruitingEarly Phase 1Roswell Park Cancer InstituteNCT06011772Written as Panitumumbab
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRCActive, not recruitingPhase 2University of Wisconsin, MadisonNCT04587128Written as Panitumumab
- Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal CancerActive, not recruitingPhase 2Australasian Gastro-Intestinal Trials GroupNCT05694936Written as Panitumumab
- Botensilimab and Balstilimab Optimization in Colorectal CancerActive, not recruitingPhase 2Nicholas DeVito, MDNCT06268015Written as Panitumumab
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Panitumumab
- A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal CancersTerminatedPhase 1MapKure, LLCNCT06194877Written as Panitumumab
- CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without PanitumumabActive, not recruitingPhase 1/2Anup KasiNCT05121038Written as Panitumumab
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedPhase 1Biosplice Therapeutics, Inc.NCT05084859Written as Panitumumab
Showing 20 of 32.
As the comparator · 5 — what is tested is compared with Panitumumab
- Pharmacokinetic (PK) Study of QL1203 and Vectibix® for the Treatment of RAS Wild-type Metastatic Colorectal CancerNot yet recruitingPhase 1Qilu Pharmaceutical Co., Ltd.NCT07829588Written as Vectibix®+ mFOLFOX6
- PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse SequenceCompletedPhase 2Gruppo Oncologico del Nord-OvestNCT04787341Written as Panitumumab
- 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCCWithdrawnPhase 2Andrei IagaruNCT05423197Written as Panitumumab
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerCompletedPhase 2Federation Francophone de Cancerologie DigestiveNCT03186326Written as Panitumumab
- Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.Status unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT04234594Written as Vectibix®
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call Panitumumab · ClinicalTrials.gg INT006741
- MeSH (NLM) D000077544PanitumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6A901E312APANITUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 263034Confirmed FDA, Wikidata
- Wikidata Q417775panitumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1857PanitumumabOne source FDA
- DrugBank DB01269One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077544 | Panitumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6A901E312A | PANITUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 263034 | — | Confirmed FDA, Wikidata |
| Wikidata | Q417775 | panitumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1857 | Panitumumab | One source FDA |
| DrugBank | DB01269 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.